<p>Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the <a href="https://www.childrensoncologygroup.org/">Children’s Oncology Group (COG)</a>, have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure. The findings <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00637-X/fulltext">published in The Lancet Oncology</a> show that the blood vessel relaxing medication carvedilol is safe for childhood cancer survivors to take and may improve important markers of heart injury sustained as a result of chemotherapy exposure.</p>